Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,677 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Study Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

NCT06847464
View directory record Official record
Conditions
RSV Infection, Drug Drug Interaction (DDI)
Interventions
EDP-323, Itraconazole, carbamazepine, Quinidine, fluconazole
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

NCT04138849
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877 single dose, Placebo single dose
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

NCT03375138
View directory record Official record
Conditions
Healthy Volunteers
Interventions
belatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

NCT06722417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

NCT05999513
View directory record Official record
Conditions
Healthy Participants
Interventions
casdatifan
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Jul 21, 2026, 12:53 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Zelquistinel in Fasted or Fed State

NCT07099989
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Zelquistinel 3 mg, Zelquistinel 10 mg
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

NCT07396909
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MT-701
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

NCT04493567
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

NCT03318809
View directory record Official record
Conditions
Heart Failure
Interventions
AMG 986
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

NCT01810432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, High-fat Meal
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

NCT06286033
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-181, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

NCT03636204
View directory record Official record
Conditions
Healthy, Frontotemporal Dementia
Interventions
AL001, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

NCT00886093
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2009 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06882961 20MG
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

NCT02906813
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-935 Tablets, TAK-935 Oral Solution
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Jul 21, 2026, 12:53 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of RBI-4000 in Healthy Participants

NCT06048770
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RBI-4000, RabAvert
Biological
Lead sponsor
Replicate Bioscience
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Miami, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of The Study Medicine Called Phenytoin Are Taken up Into the Blood in Healthy Adults

NCT06466473
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (Ascoli), Phenytoin (Vega Baja)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2623091 in Healthy Participants

NCT02300259
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2623091, Itraconazole, Simvastatin, Tadalafil, Diltiazem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Osteopathic Manipulation on Circulating Immune Markers

NCT07622966
View directory record Official record
Conditions
Healthy Adult Participants, Osteopathic Manipulative Treatment (OMT)
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Comparator
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Monroe, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of IXT-m200

NCT05027451
View directory record Official record
Conditions
Healthy
Interventions
IXT-m200, Placebo
Drug · Other
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

NCT03859323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP681, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jul 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

NCT04016077
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
PF-06651600 30 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 21, 2026, 12:53 PM EDT